Healthcare & Pharmaceuticals
AI-based CRC II/III Prognosis
A deep learning-based algorithm applied to H&E digitised slide images of tumour tissue to stratify CRC patients into low- or high-risk of relapse of the cancer after surgery.
Field of Expertise
Artificial Intelligence , image processing, software development, product commercialisation
Expertise
Lead the company’s in-vitro-diagnosis product development including developing a deep learning based software system for analysing the slide image of the tumour sample tissue of Stage II/III colorectal cancer patient to predict the risk of the relapse of the cancer after surgery and therefore to help the doctor and the patient to make an informed clinical decision whether a better-targeted adjuvant chemotherapy for high-risk patients or avoiding chemotherapy for low-risk patient.